Table 2.
Ocular pharmacokinetics and patient factors according to the brimonidine-related studied
| Ocular pharmacokinetics | n | Over all | Study | |||||
|---|---|---|---|---|---|---|---|---|
| Aiphagan | Aibeta | Ailamide | ||||||
| Median (IQR) | n | Median (IQR) | n | Median (IQR) | n | Median (IQR) | ||
| Aqueous humor concentrations (nM) | ||||||||
| Brimonidine | 40 | 294 (160–542) | 22 | 229 (120–579) | 8 | 294 (181–515) | 10 | 432 (172–521) |
| Timolol | 8 | 3220 (1870–4620) | – | NA | 8 | 3220 (1870–4620) | – | NA |
| Brinzolamide | 10 | 840 (521–1710) | – | NA | – | NA | 10 | 840 (521–1710) |
| Vitreous humor concentrations (nM) | ||||||||
| Brimonidine | 42 | 3.69 (2.70–6.11) | 24 | 3.48 (2.81–5.94) | 8 | 3.77 (1.47–8.75) | 10 | 5.15 (3.19–6.00) |
| Timolol | 8 | 48.6 (21.8–108) | – | NA | 8 | 48.6 (21.8–108) | – | NA |
| Brinzolamide | 10 | 8.23 (4.94–10.8) | – | NA | – | NA | 10 | 8.23 (4.94–10.8) |
| Patient factors | ||||||||
| Corneal thickness (µm) | 18 | 528 (512–552) | – | NA | 8 | 530 (513–569) | 10 | 528 (507–549) |
| Corneal endothelial cell density | 18 | 2535 (2393–2712) | – | NA | 8 | 2501 (2261–2790) | 10 | 2535 (2434–2712) |
| Tear secretion (mm) | 17 | 6 (4–9) | – | NA | 7 | 8 (5–9) | 10 | 5 (4–14) |
| Eye axial length (mm) | 18 | 24.3 (23.5–25.8) | – | NA | 8 | 23.9 (22.6–25.8) | 10 | 24.5 (23.6–26.2) |
| Height (cm) | 42 | 158 (151–163) | 24 | 155 (150–162) | 8 | 159 (153–170) | 10 | 158 (150–164) |
| Weight (kg) | 42 | 57.2 (50.9–60.3) | 24 | 57.6 (51.1–60.1) | 8 | 57.5 (50.0–70.4) | 10 | 53.6 (49.8–61.9) |
| BMI | 42 | 22.9 (21.3–25.0) | 24 | 22.8 (22.0–25.2) | 8 | 23.3 (20.1–25.1) | 10 | 22.7 (19.0–25.1) |
IQR interquartile range, NA not applicable, BMI body mass index